Skip to main content

Bachrodt Amy's Form 4 filing

Maze Therapeutics, Inc. (MAZE) · filed Feb 4, 2026

Accession no.
0002050422-26-000008
Filed
Feb 4, 2026
Trade date
Feb 2, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $230.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bachrodt AmyCIK 0002050422Officer (SVP, Finance)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 2, 2026Common StockMOption exerciseAcquired+4,844$10.42+$50,474.4817,809Direct
Feb 2, 2026Common StockMOption exerciseAcquired+156$10.42+$1,625.5217,965Direct
Feb 2, 2026Common StockSSaleDisposed−200$44.15−$8,83017,765Direct
Feb 2, 2026Common StockSSaleDisposed−4,064$46.03−$187,065.9213,701Direct
Feb 2, 2026Common StockSSaleDisposed−736$46.63−$34,319.6812,965Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 2, 2026Common StockMOption exerciseDisposed−4,844$0.00$03,025Direct
Feb 2, 2026Common StockMOption exerciseDisposed−156$0.00$041,333Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)